In the context of TKI response, we found that CML patients with AG genotypes for this variant have a higher risk of BCR::ABL1 mutations, which are highly associated with TKI resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.